Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PRAVEEN KUMAR TUMULA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1447402896
CMS profile
746364
Location
AMARILLO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$340.16

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $179.92 3
Food and Beverage $160.24 3

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Epizyme, Inc., $125.00 1
Seagen Inc. $95.00 1
Incyte Corporation $60.99 1
Myovant Sciences Inc. $23.93 1
Amgen Inc. $21.12 1
JAZZ PHARMACEUTICALS INC. $14.12 1

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PRAVEEN KUMAR TUMULA

NPI 1447402896 · CMS profile ID 746364

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

AMARILLO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447402896?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PRAVEEN KUMAR TUMULA, NPI 1447402896, CMS profile ID 746364. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447402896?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). PRAVEEN KUMAR TUMULA, NPI 1447402896, CMS profile ID 746364. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447402896?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
PRAVEEN KUMAR TUMULA, NPI 1447402896, CMS profile ID 746364, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1447402896?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $340.16 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Epizyme, Inc., $125.0011/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832343341 CMS
JAZZ PHARMACEUTICALS INC. $14.1211/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845605919 CMS
Seagen Inc. $95.0006/08/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832188317 CMS
Incyte Corporation $60.9905/03/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835550457 CMS
Myovant Sciences Inc. $23.9304/14/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834994241 CMS
Amgen Inc. $21.1201/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826537917 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,168.66 28
PY2020 $4,815.65 8
PY2021 $340.16 6
PY2022 $1,916.32 26
PY2023 $4,540.57 16
PY2024 $2,679.61 6
PY2025 $6,258.84 11

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $604,557.82 36
PY2024 Principal investigator $1,085,444.24 161
PY2023 Principal investigator $684,815.25 77
PY2022 Principal investigator $638,195.90 127
PY2021 Principal investigator $416,830.90 164
PY2020 Principal investigator $201,522.62 122
PY2019 Recipient $1,287.72 1
PY2019 Principal investigator $54,363.67 98

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

99 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $105.00 12/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452295
Principal investigator 1 Incyte Corporation $489.00 12/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452297
Principal investigator 1 Incyte Corporation $105.00 12/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452307
Principal investigator 1 Incyte Corporation $105.00 12/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452309
Principal investigator 1 Incyte Corporation $489.00 12/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452311
Principal investigator 1 Incyte Corporation $489.00 12/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452313
Principal investigator 1 Incyte Corporation $105.00 12/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452315
Principal investigator 1 Incyte Corporation $489.00 12/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452317
Principal investigator 1 Incyte Corporation $1,147.78 12/12/2019 Non-covered Recipient Entity
VIRGINIA CANCER SPECIALISTS-FAIRFAX
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666460141
Principal investigator 1 Incyte Corporation $105.00 11/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452291
Principal investigator 1 Incyte Corporation $489.00 11/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452293
Principal investigator 1 Incyte Corporation $489.00 11/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452305
Principal investigator 1 Celgene Corporation $315.00 11/13/2019 Non-covered Recipient Entity
Advarra, Inc.
Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry (NCT01688011) No dispute reported 06/30/2026 675415979
Principal investigator 1 Incyte Corporation $68.40 11/08/2019 Non-covered Recipient Entity
MCKESSON SPECIALTY PHARMACY LP
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666519019
Principal investigator 1 Incyte Corporation $0.80 11/08/2019 Non-covered Recipient Entity
MCKESSON SPECIALTY PHARMACY LP
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666519021
Principal investigator 1 Incyte Corporation $76.64 11/08/2019 Non-covered Recipient Entity
MCKESSON SPECIALTY PHARMACY LP
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666519023
Principal investigator 1 Incyte Corporation $22.80 11/08/2019 Non-covered Recipient Entity
MCKESSON SPECIALTY PHARMACY LP
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666519025
Principal investigator 1 Incyte Corporation $176.00 11/08/2019 Non-covered Recipient Entity
MCKESSON SPECIALTY PHARMACY LP
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666519027
Principal investigator 1 Incyte Corporation $68.40 11/08/2019 Non-covered Recipient Entity
MCKESSON SPECIALTY PHARMACY LP
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666519029
Principal investigator 1 Incyte Corporation $2.40 11/08/2019 Non-covered Recipient Entity
MCKESSON SPECIALTY PHARMACY LP
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666519031
Principal investigator 1 Incyte Corporation $109.80 11/08/2019 Non-covered Recipient Entity
MCKESSON SPECIALTY PHARMACY LP
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666519033
Principal investigator 1 Celgene Corporation $375.00 10/30/2019 Non-covered Recipient Entity
Texas Oncology, PA
Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry (NCT01688011) No dispute reported 06/30/2026 675419147
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,010.96 10/29/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment of Multiple Myeloma INSIGHT No dispute reported 06/30/2026 686167135
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,440.20 10/22/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment of Multiple Myeloma INSIGHT No dispute reported 06/30/2026 686167225
Principal investigator 1 Incyte Corporation $105.00 10/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452285
Principal investigator 1 Incyte Corporation $489.00 10/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452287
Principal investigator 1 Incyte Corporation $850.00 10/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452289
Principal investigator 1 Incyte Corporation $489.00 10/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452299
Principal investigator 1 Incyte Corporation $489.00 10/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452301
Principal investigator 1 Incyte Corporation $105.00 10/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452303
Principal investigator 1 Incyte Corporation $4,705.19 09/13/2019 Non-covered Recipient Entity
VIRGINIA CANCER SPECIALISTS-FAIRFAX
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666460111
Principal investigator 1 Celgene Corporation $143.00 09/02/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCH, INC.
A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) (CC-5013-NHL-008) No dispute reported 06/30/2026 675419695
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,440.20 08/27/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment of Multiple Myeloma INSIGHT No dispute reported 06/30/2026 686167227
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $858.48 08/27/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment of Multiple Myeloma INSIGHT No dispute reported 06/30/2026 686167229
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $858.48 08/27/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment of Multiple Myeloma INSIGHT No dispute reported 06/30/2026 686167231
Principal investigator 1 Incyte Corporation $489.00 08/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452257
Principal investigator 1 Incyte Corporation $105.00 08/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452259
Principal investigator 1 Incyte Corporation $489.00 08/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452261
Principal investigator 1 Incyte Corporation $105.00 08/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452263
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,581.72 08/01/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment of Multiple Myeloma INSIGHT No dispute reported 06/30/2026 686167133
Principal investigator 1 Incyte Corporation $5,165.01 07/17/2019 Non-covered Recipient Entity
VIRGINIA CANCER SPECIALISTS-FAIRFAX
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666459995
Principal investigator 1 Incyte Corporation $850.00 07/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452251
Principal investigator 1 Incyte Corporation $105.00 07/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452253
Principal investigator 1 Incyte Corporation $489.00 07/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452255
Principal investigator 1 Incyte Corporation $32.00 07/10/2019 Non-covered Recipient Entity
MCKESSON SPECIALTY PHARMACY LP
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666518841
Principal investigator 1 Incyte Corporation $22.08 07/10/2019 Non-covered Recipient Entity
MCKESSON SPECIALTY PHARMACY LP
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666518847
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,146.20 06/25/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment of Multiple Myeloma INSIGHT No dispute reported 06/30/2026 686167137
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,581.72 06/18/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment of Multiple Myeloma INSIGHT No dispute reported 06/30/2026 686167223
Principal investigator 1 Incyte Corporation $489.00 06/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452215
Principal investigator 1 Incyte Corporation $105.00 06/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452217
Principal investigator 1 Incyte Corporation $105.00 05/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452211
Principal investigator 1 Incyte Corporation $489.00 05/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452213
Principal investigator 1 Incyte Corporation $105.00 05/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452237
Principal investigator 1 Incyte Corporation $489.00 05/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452239
Principal investigator 1 Incyte Corporation $489.00 05/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452241
Principal investigator 1 Incyte Corporation $105.00 05/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452243
Principal investigator 1 Incyte Corporation $489.00 05/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452245
Principal investigator 1 Incyte Corporation $0.75 05/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.- MCALLEN
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666511295
Principal investigator 1 Incyte Corporation $54.90 05/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.- MCALLEN
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666511297
Principal investigator 1 Incyte Corporation $0.40 05/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.- MCALLEN
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666511299
Principal investigator 1 Incyte Corporation $76.64 05/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.- MCALLEN
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666511367
Principal investigator 1 Incyte Corporation $57.00 05/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.- MCALLEN
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666511369
Principal investigator 1 Incyte Corporation $105.00 04/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452205
Principal investigator 1 Incyte Corporation $489.00 04/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452207
Principal investigator 1 Incyte Corporation $850.00 04/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452209
Principal investigator 1 Incyte Corporation $489.00 04/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452219
Principal investigator 1 Incyte Corporation $105.00 04/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452221
Principal investigator 1 Incyte Corporation $489.00 04/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452223
Principal investigator 1 Incyte Corporation $489.00 04/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452225
Principal investigator 1 Incyte Corporation $105.00 04/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452227
Principal investigator 1 Incyte Corporation $105.00 04/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452229
Principal investigator 1 Incyte Corporation $105.00 04/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452231
Principal investigator 1 Incyte Corporation $489.00 04/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452233
Principal investigator 1 Incyte Corporation $489.00 04/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452235
Principal investigator 1 Incyte Corporation $4,819.26 04/15/2019 Non-covered Recipient Entity
VIRGINIA CANCER SPECIALISTS-FAIRFAX
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666459915
Principal investigator 1 Celgene Corporation $323.00 04/09/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCH, LLC
A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) (CC-5013-NHL-008) No dispute reported 06/30/2026 675419729
Principal investigator 1 Incyte Corporation $489.00 03/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452275
Principal investigator 1 Incyte Corporation $105.00 03/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452277
Principal investigator 1 Incyte Corporation $57.00 03/08/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452193
Principal investigator 1 Incyte Corporation $0.40 03/08/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452195
Principal investigator 1 Incyte Corporation $54.90 03/08/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452197
Principal investigator 1 Incyte Corporation $1.50 03/08/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452199
Principal investigator 1 Incyte Corporation $57.00 03/08/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452201
Recipient Takeda Pharmaceuticals U.S.A., Inc. $1,287.72 02/07/2019 Covered Recipient Physician The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment of Multiple Myeloma INSIGHT No dispute reported 06/30/2026 686158275
Principal investigator 1 Incyte Corporation $0.48 01/28/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452183
Principal investigator 1 Incyte Corporation $264.00 01/28/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452185
Principal investigator 1 Incyte Corporation $65.88 01/28/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452187
Principal investigator 1 Incyte Corporation $68.40 01/28/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452189
Principal investigator 1 Incyte Corporation $0.90 01/28/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452191
Principal investigator 1 Celgene Corporation $2,250.00 01/18/2019 Non-covered Recipient Entity
Texas Oncology, PA
Celgene - Connect MDSAML No dispute reported 06/30/2026 675419149
Principal investigator 1 Celgene Corporation $218.00 01/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) (CC-5013-NHL-008) No dispute reported 06/30/2026 675419089
Principal investigator 1 Incyte Corporation $489.00 01/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452265
Principal investigator 1 Incyte Corporation $105.00 01/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452267
Principal investigator 1 Incyte Corporation $850.00 01/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452269
Principal investigator 1 Incyte Corporation $1,074.00 01/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452271
Principal investigator 1 Incyte Corporation $42.00 01/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452273
Principal investigator 1 Incyte Corporation $105.00 01/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452279
Principal investigator 1 Incyte Corporation $105.00 01/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452281
Principal investigator 1 Incyte Corporation $489.00 01/15/2019 Non-covered Recipient Entity
TX ONC AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666452283